In vivo inhibition of RIPK2 kinase alleviates inflammatory disease.
Tigno-Aranjuez, Justine T; Benderitter, Pascal; Rombouts, Frederik; Deroose, Frederik; Bai, XiaoDong; Mattioli, Benedetta; Cominelli, Fabio; Pizarro, Theresa T; Hoflack, Jan; Abbott, Derek W.
J Biol Chem
; 289(43): 29651-64, 2014 Oct 24.
Artigo em Inglês | MEDLINE | ID: mdl-25213858
Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease.
Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors.
Identification of Novel Protein Kinase Receptor Type 2 Inhibitors Using Pharmacophore and Structure-Based Virtual Screening.
Catalytic in vivo protein knockdown by small-molecule PROTACs.
RNAi screening identifies mediators of NOD2 signaling: implications for spatial specificity of MDP recognition.
OTULIN restricts Met1-linked ubiquitination to control innate immune signaling.
RIP2 enhances cell survival by activation of NF-Ä¸B in triple negative breast cancer cells.
Activity of SHIP, Which Prevents Expression of Interleukin 1ß, Is Reduced in Patients With Crohn's Disease.
Cigarette Smoke Modulates NOD1 Signal Pathway and Human ß Defensins Expression in Human Oral Mucosa.
HIV-1 protease cleaves the serine-threonine kinases RIPK1 and RIPK2.